Celyad Oncology S.A.
Other OTCTotal Valuation
Celyad Oncology S.A. carries a market capitalization of 11.19M, placing it among publicly traded companies globally. Its enterprise value stands at -12.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 11.19M |
| Enterprise Value | -12.22M |
Share Statistics
Celyad Oncology S.A. currently has 22.59M shares outstanding.
| Shares Outstanding | 22.59M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Celyad Oncology S.A. maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.06, indicating elevated leverage, while an interest coverage ratio of -122.57 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.71 |
| Quick Ratio | 1.59 |
| Debt / Equity | 7.06 |
| Debt / EBITDA | -0.07 |
| Interest Coverage | -122.57 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -40.87 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 10,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Celyad Oncology S.A.'s stock has declined approximately -50% over the past 52 weeks. The 50-day moving average sits at 0.25, while the 200-day moving average is 0.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | -50% |
| 50-Day Moving Average | 0.25 |
| 200-Day Moving Average | 0.24 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -29.29M, while operating income came in at -29.29M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -29.29M |
| Pretax Income | -25.70M |
| Net Income | -25.71M |
| EBITDA | -29.29M |
| EBIT | -29.29M |
| Earnings Per Share (EPS) | -1.15 |
Balance Sheet
Celyad Oncology S.A. holds 14.39M in cash and equivalents against 2.16M in total debt, resulting in a net debt position of -14.38M. Total book value stands at -244.47M, with working capital of 8.02M providing operational flexibility.
| Cash & Cash Equivalents | 14.39M |
| Total Debt | 2.16M |
| Net Debt | -14.38M |
| Equity (Book Value) | -244.47M |
| Book Value Per Share | -10.98 |
| Working Capital | 8.02M |
Scores
Celyad Oncology S.A. posts an Altman Z-Score of -20.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.31 |